北京大学学报(医学版) ›› 2017, Vol. 49 ›› Issue (3): 547-550. doi: 10.3969/j.issn.1671-167X.2017.03.029

• 技术方法 • 上一篇    下一篇

单纯放射性粒子治疗后的头颈部腺源性癌远处转移

王威,郑磊,刘树铭,黄明伟,石妍,吕晓鸣,张杰△,张建国   

  1. (北京大学口腔医学院·口腔医院, 口腔颌面外科口腔数字化医疗技术和材料国家工程实验室口腔数字医学北京市重点实验室, 北京100081)
  • 出版日期:2017-06-18 发布日期:2017-06-18
  • 通讯作者: 张杰 E-mail:zhangjie06@126.com

Distant metastases of malignant salivary gland carcinoma after treated by 125Ⅰinternal brachy therapy alone

WANG Wei, ZHENG Lei, LIU Shu-ming, HUANG Ming-wei, SHI Yan, LV Xiao-ming, ZHANG Jie△, ZHANG Jian-guo   

  1. (Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology & National Engi-neering Laboratory for Digital and Material Technology of Stomatology & Beijing Key Laboratory of Digital Stomatology, Beijing 100081, China)
  • Online:2017-06-18 Published:2017-06-18
  • Contact: ZHANG Jie E-mail:zhangjie06@126.com

摘要:  目的:探讨单纯125I粒子治疗后头颈部腺源性癌远处转移的一般规律。方法:2002年至2010年就诊于北京大学口腔医院口腔颌面外科的头颈部腺源性癌患者43例,因全身或局部因素不能进行手术切除,行单纯125I放射性粒子组织间植入治疗,肿瘤部位包括腮腺、颅底颞下窝、舌、上颌、咽旁、口底、颌下、唇。术后随访观察,统计局部控制率、生存率及远处转移情况。结果:远处转移率为53.5%(23/43);转移发生时间为5~96个月,平均时间(27.0±23.7)个月,中位时间21个月;肺为最常见转移部位(16/23,69.6%);远处转移常见病理类型为腺样囊性癌(14/23,60.9%)和非特异性腺癌(7/23,30.4%)。最终死亡26例,其中18例因转移而死亡,占所有死亡患者的69.2%(18/26)。27例获得了肿瘤完全消退(完全缓解,complete remission,CR),12例消退大于50%(部分缓解,partial remission,PR),2例消退小于50%,2例无效,有效率(CR+ PR)为90.7%。3年局部控制率和生存率分别为60.1%和82.6%,5年分别为53.4%和56.0%。结论:对于手术禁忌或无法切除的头颈部腺源性癌,单纯125I放射性粒子组织间植入可以取得良好的近期疗效,但远期疗效仍有待进一步观察。远处转移是治疗失败的主要原因,肺为最常见的部位。

关键词: 头颈部肿瘤, 涎腺肿瘤, 肿瘤转移, 近距离放射疗法, 碘放射性同位素

Abstract: Objective: To investigate clinical features of distant metastases from malignant salivary gland carcinomas after treated by 125I internal brachy therapy alone. Methods: Between 2002 and 2010, 43 patients with locally advanced unresectable or recurrent malignant salivary gland carcinomas were treated by 125I internal brachy therapy alone at Peking University School and Hospital of Stomatology. All of them had been follow-up at least 2 years. The primary sites of malignant salivary gland carcinomas were the parotid for 12 patients, infratemporal fossa for 9 patients, tongue for 7 patients, maxilla for 6 patients, parapharyngeal for 4 patients, floor of months for 3 patients, submandibular gland for 1 patient, and lip for 1 patient. The overall survival rate, local control rate, and distant metastases were retrospectively reviewed. Results: Distant metastases occurred in 23 of the 43 patients (53.5%). Distant metastases developed from 5 to 96 months, with an average interval of (27.0±23.7) months from the time of initial diagnosis, the mean interval was 21 months. The commonest site of distant metastases overall was the lung 69.6%(16/23). The most common pathological types of distant metastases were adenoid cystic carcinoma (14/23, 60.9%) and nonspecific adenocarcinoma (7/23, 30.4%). At the time of the last follow-up, 26 patients died, and 18 of them due to distant metastases (69.2%, 18/26). In the study, 27 patients got complete remission(CR), 12 got partial remission(PR) more than 50%, 2 less than 50%, and 2 patients were invalid. The effective rate (CR+ PR) was 90.7%. The 3 year loco-regional control rate and survival rate were 60.1%, 82.6%, respectively, and the 5 year’s 53.4% and 56.0%. Conclusion: The 125I brachy therapy is a feasible and effective modality for the treatment of locally advanced unresectable or recurrent malignant salivary gland carcinomas. However, further studies are needed with larger numbers of patients and for a longer follow-up assessment. Distant metastasis was the main cause of treatment failure, and the lung was the most common site of distant metastases.

Key words: Head and neck neoplasms, Salivary gland neoplasms, Neoplasm metastasis, Brachy therapy, Iodine radioisotopes

中图分类号: 

  •  
[1] 王跃,张爽,张虹,梁丽,徐玲,程元甲,段学宁,刘荫华,李挺. 激素受体阳性/人表皮生长因子受体2阴性乳腺癌临床病理特征及预后[J]. 北京大学学报(医学版), 2022, 54(5): 853-862.
[2] 于焕斌,伍文杰,吕晓鸣,石妍,郑磊,张建国. 125I粒子近距离治疗外放疗后复发唾液腺癌[J]. 北京大学学报(医学版), 2020, 52(5): 919-923.
[3] 李潇,苏家增,张严妍,张丽琪,张亚琼,柳登高,俞光岩. 131I相关唾液腺炎的炎症分级及内镜治疗[J]. 北京大学学报(医学版), 2020, 52(3): 586-590.
[4] 张晔,张妮,刘晓筱,周传香. 唾液腺腺样囊性癌淋巴结转移相关的临床病理分析[J]. 北京大学学报(医学版), 2020, 52(1): 30-34.
[5] 张旭初,张建华,王荣福,范岩,付占立,闫平,赵光宇,白艳霞. 18F-FDG PET/CT联合多种肿瘤标志物在结直肠中分化腺癌术后复发及转移中的应用价值[J]. 北京大学学报(医学版), 2019, 51(6): 1071-1077.
[6] 王晶,陈俊鹏,王洋,许向亮,郭传瑸. 数字化下颌运动记录及咀嚼肌肌电图在下颌骨肿瘤患者口颌功能评价中的应用[J]. 北京大学学报(医学版), 2019, 51(3): 571-578.
[7] 李聪,刘树铭,郑磊,黄明伟,石妍,吕晓鸣,张建国,张杰. 手术联合 125I粒子治疗口腔颌面部腺样囊性癌的疗效与相关预后因素分析[J]. 北京大学学报(医学版), 2019, 51(1): 49-52.
[8] 黄子雄,杜依青,张晓鹏,刘士军,徐涛. 肾细胞癌骨转移的临床与病理分析[J]. 北京大学学报(医学版), 2018, 50(5): 811-815.
[9] 黄子雄,张晓鹏,董森,刘士军,杨荣利,周宇石,马伟国. 肾黏液性小管和梭形细胞癌合并骨转移1例及文献回顾[J]. 北京大学学报(医学版), 2018, 50(4): 732-735.
[10] 李健男,冯芝恩,王琳,王衣祥,郭传瑸. 乏氧诱导因子-1α在口腔鳞状细胞癌颈淋巴转移中的作用[J]. 北京大学学报(医学版), 2018, 50(1): 26-32.
[11] 叶克强,黄明伟,李君利,唐劲天,张建国. 125I放射性粒子在骨介质中剂量分布的蒙特卡罗模拟[J]. 北京大学学报(医学版), 2018, 50(1): 131-135.
[12] 赵轶国,杨晓东,张雁凯,宁宁,邢兆东,叶颖江. 美克尔憩室癌变及肝多发转移并消化道出血1例[J]. 北京大学学报(医学版), 2017, 49(6): 1095-1097.
[13] 于尧, 章文博, 王洋, 刘筱菁, 郭传瑸, 俞光岩, 彭歆. iPlan CMF软件辅助下增强CT三维重建在头颈部肿瘤治疗中的应用[J]. 北京大学学报(医学版), 2017, 49(5): 878-882.
[14] 郭福新,姜玉良,吉喆,彭冉,孙海涛,王俊杰. 3D打印非共面模板辅助CT引导125Ⅰ粒子植入治疗锁骨上复发转移癌的剂量学研究[J]. 北京大学学报(医学版), 2017, 49(3): 506-511.
[15] 方伟岗,田新霞. 肿瘤微环境中一种新型促侵袭因子的发现——细胞外ATP功能及机制的研究进展[J]. 北京大学学报(医学版), 2017, 49(2): 188-195.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!